A 35-year-old man with newly diagnosed HIV presents with a 2-week history of severe odynophagia and dysphagia. His CD4+ count is 120/μL. Upper endoscopy reveals the findings marked as **A** in the diagram—white-yellow adherent plaques on erythematous and friable esophageal mucosa. Which of the following is the most appropriate initial management in this high-pretest-probability patient?
A. Esophageal manometry to exclude achalasia before initiating antifungal treatment
B. IV amphotericin B deoxycholate as first-line therapy due to severity of immunosuppression
C. Immediate esophageal biopsy with PAS staining to confirm Candida albicans before any antifungal therapy
D. Empirical oral fluconazole 200-400 mg daily for 14-21 days with clinical response assessment
Explanation
Why Empirical oral fluconazole 200-400 mg daily for 14-21 days with clinical response assessment is right
In a high-pretest-probability patient with HIV/AIDS (CD4 <200/μL), characteristic odynophagia, dysphagia, and the classic endoscopic finding of white-yellow adherent pseudomembranous plaques on erythematous mucosa (marked A), the diagnosis of esophageal candidiasis is made empirically without awaiting histological confirmation. According to the IDSA Candidiasis Guideline 2016, oral fluconazole 200-400 mg daily for 14-21 days is the first-line treatment and achieves cure rates of 80-100%. Clinical response within 3-7 days confirms the diagnosis. This approach is cost-effective, avoids unnecessary delay, and is standard of care in resource-limited and resource-rich settings.
Why each distractor is wrong
Immediate esophageal biopsy with PAS staining to confirm Candida albicans before any antifungal therapy: While endoscopy with brushings and biopsies showing yeast forms and pseudohyphae on PAS/GMS stain confirms the diagnosis, this is NOT required in high-pretest-probability patients. Endoscopy is reserved for cases with no response to empirical therapy, atypical presentations, or lower pretest probability to exclude CMV, HSV, or other coexisting infections. Delaying treatment while awaiting histology is inappropriate and causes unnecessary suffering.
IV amphotericin B deoxycholate as first-line therapy due to severity of immunosuppression: IV amphotericin B is reserved for fluconazole-refractory disease, patients unable to swallow due to severe odynophagia (who may start IV therapy then switch to oral), or non-albicans species. It is NOT first-line and carries significant nephrotoxicity. Oral fluconazole is effective even in severe immunosuppression (CD4 <200) when the patient can swallow.
Esophageal manometry to exclude achalasia before initiating antifungal treatment: While achalasia and other esophageal motility disorders are risk factors for candidiasis due to stasis, manometry is not part of the diagnostic or management algorithm for esophageal candidiasis. The characteristic endoscopic appearance (white-yellow plaques on erythematous mucosa) is diagnostic of candidiasis, not achalasia. Manometry would delay necessary treatment.
High-YieldNEET PG
In high-pretest-probability esophageal candidiasis (HIV/AIDS with CD4 <200, odynophagia, and characteristic plaques), empirical oral fluconazole 200-400 mg daily for 14-21 days is standard; clinical response within 3-7 days confirms diagnosis—endoscopy is for non-responders or atypical cases.
